95 related articles for article (PubMed ID: 31983122)
21. A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma.
Pei C; Chen H; Jia X; Yan L; Zou Y; Jiang C; Jin H; Kang C; Jiang T; Ren H
Int J Neurosci; 2013 Feb; 123(2):114-20. PubMed ID: 23057844
[TBL] [Abstract][Full Text] [Related]
22. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
Lehrer S; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
[TBL] [Abstract][Full Text] [Related]
23. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
24. SSBP2 variants are associated with survival in glioblastoma patients.
Xiao Y; Decker PA; Rice T; McCoy LS; Smirnov I; Patoka JS; Hansen HM; Wiemels JL; Tihan T; Prados MD; Chang SM; Berger MS; Kosel ML; Fridley BL; Lachance DH; O'Neill BP; Buckner JC; Thompson RC; Nabors LB; Olson JJ; Brem S; Madden MH; Browning JE; Wiencke JK; Egan KM; Jenkins RB; Wrensch MR
Clin Cancer Res; 2012 Jun; 18(11):3154-62. PubMed ID: 22472174
[TBL] [Abstract][Full Text] [Related]
25. A vascular endothelial growth factor gene polymorphism predicts malignant potential in intraductal papillary mucinous neoplasm.
Yabusaki N; Yamada S; Shimoyama Y; Fujii T; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
Pancreas; 2015 May; 44(4):608-14. PubMed ID: 25875799
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
[TBL] [Abstract][Full Text] [Related]
27. The functional Aquaporin 1 -783G/C-polymorphism is associated with survival in patients with glioblastoma multiforme.
El Hindy N; Rump K; Lambertz N; Zhu Y; Frey UH; Bankfalvi A; Siffert W; Sure U; Peters J; Adamzik M; Sandalcioglu IE
J Surg Oncol; 2013 Dec; 108(7):492-8. PubMed ID: 24014128
[TBL] [Abstract][Full Text] [Related]
28. Correlations of EGF G1380A, bFGF C754G and VEGF T460C polymorphisms with malignant melanoma susceptibility and prognosis: A case-control study.
Wang XH; Long ZW
Gene; 2017 Jun; 617():44-53. PubMed ID: 28219779
[TBL] [Abstract][Full Text] [Related]
29. Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy.
Pasqualetti F; Gonnelli A; Cantarella M; Delishaj D; Molinari A; Ortenzi V; Carbone F; Montrone S; Ursino S; Franceschi S; Morganti R; Orlandi P; Di Desidero T; Mazzanti CM; Zavaglia K; Naccarato AG; Bocci G; Paiar F
Invest New Drugs; 2018 Apr; 36(2):340-345. PubMed ID: 28965273
[TBL] [Abstract][Full Text] [Related]
30. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Rulseh AM; Vymazal J
J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
[TBL] [Abstract][Full Text] [Related]
31. No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis.
Boisselier B; Marie Y; El Hallani S; Kaloshi G; Iershov A; Kavsan V; Psimaras D; Thillet J; Hoang-Xuan K; Delattre JY; Sanson M
J Neurooncol; 2009 Sep; 94(2):169-72. PubMed ID: 19255724
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival.
Liu Y; Shete S; Etzel CJ; Scheurer M; Alexiou G; Armstrong G; Tsavachidis S; Liang FW; Gilbert M; Aldape K; Armstrong T; Houlston R; Hosking F; Robertson L; Xiao Y; Wiencke J; Wrensch M; Andersson U; Melin BS; Bondy M
J Clin Oncol; 2010 May; 28(14):2467-74. PubMed ID: 20368557
[TBL] [Abstract][Full Text] [Related]
33. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.
Marenco-Hillembrand L; Wijesekera O; Suarez-Meade P; Mampre D; Jackson C; Peterson J; Trifiletti D; Hammack J; Ortiz K; Lesser E; Spiegel M; Prevatt C; Hawayek M; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2020 Apr; 147(2):297-307. PubMed ID: 32157552
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
35. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
[TBL] [Abstract][Full Text] [Related]
36. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Oh SW; Jee TK; Kong DS; Nam DH; Lee JI; Seol HJ
Acta Neurochir (Wien); 2014 Apr; 156(4):641-51. PubMed ID: 24553726
[TBL] [Abstract][Full Text] [Related]
37. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y
Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
[TBL] [Abstract][Full Text] [Related]
39. Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme.
Simon M; Ludwig M; Fimmers R; Mahlberg R; Müller-Erkwoh A; Köster G; Schramm J
Neurosurgery; 2006 Nov; 59(5):1078-85; discussion 1085. PubMed ID: 17016233
[TBL] [Abstract][Full Text] [Related]
40. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.
Vauleon E; Auger N; Benouaich-Amiel A; Laigle-Donadey F; Kaloshi G; Lejeune J; Delattre JY; Thillet J; Sanson M
Cancer Genet Cytogenet; 2007 Jan; 172(1):33-7. PubMed ID: 17175377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
